AEON Biopharma, Inc.

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing botulinum toxin-based therapeutics across both aesthetic and therapeutic indications. The company accessed the public markets through a business combination with Priveterra Acquisition Corp, a healthcare-focused special purpose acquisition company that completed its initial public offering in 2021 under the Nasdaq ticker PMGM, sponsored by Priveterra Capital. Following the close of the merger, AEON Biopharma filed a Form 10-Q with the Securities and Exchange Commission on July 21, 2023, establishing its reporting obligations as a post-combination public entity advancing a pipeline of next-generation neurotoxin candidates. For complete deal analytics, filing history, and real-time SPAC data on AEON Biopharma and thousands of other transactions, sign up for full access at SpacDesk.